Survival in HIV-1 patients receiving antiretroviral therapy in Morocco

被引:1
|
作者
Titou, H. [1 ]
Baba, N. [1 ]
Kasouati, J. [2 ]
Oumakir, S. [1 ]
Frikh, R. [1 ]
Boui, M. [1 ]
Hjira, N. [1 ]
机构
[1] Univ Mohammed V Rabat, Serv Dermatol Venerol, Hop Mil Instruct Mohamed V, Hay Ryad 10100, Morocco
[2] Univ Mohammed V Rabat, Lab Biostat & Rech Clin & Epidemiol, FMPR, Rabat, Morocco
来源
关键词
Survival analysis; HIV infection; Antiretroviral therapy; PROTEASE INHIBITORS; HIV-1-INFECTED PATIENTS; INFECTED INDIVIDUALS; COHORT; MORTALITY; EFAVIRENZ; AIDS; DETERMINANTS; IMPACT; HETEROGENEITY;
D O I
10.1016/j.respe.2018.07.001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. - The purpose was to study factors associated with the survival of HIV-1 patients receiving antiretroviral therapy in Morocco. Material and method. - This was a retrospective study of a cohort of 182 HIV-1 patients receiving antiretroviral therapy in the department of dermatology venereology at the Military Instruction Hospital Mohamed V in Rabat during the period from 1 January 2006 to 1 January 2017. Death of any cause during the study period was considered to be the result of HIV infection. The log-rank test was used to compare the survival curves based on determinants. The Cox regression model analyzed the determinants of survival since induction of antiretroviral therapy. Results. - The median follow-up time was 4.7 years (IQR: 1.97-8.18). The mortality rate was 75 deaths per 1000 person-years. Advanced clinical stage CDC C (RR: 2.72; CI 95%: 1.33-5.56) and treatment with indinavir (RR: 1.41; CI 95%: 0.77-2.59) were significantly associated with death. Conclusion. - Initiation of antiretroviral therapy in the early stage of the disease and use of less toxic molecules are recommended to reduce mortality. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [31] ANTIRETROVIRAL COMBINATION THERAPY FOR HIV-1 INFECTION
    HERIDA, M
    PRESSE MEDICALE, 1995, 24 (23): : 1056 - 1058
  • [32] Antiretroviral therapy in HIV-1 infected children
    Lodha, R
    Upadhyay, A
    Kabra, SK
    INDIAN PEDIATRICS, 2005, 42 (08) : 789 - 796
  • [33] Antiretroviral Therapy for the Prevention of HIV-1 Transmission
    Cohen, M. S.
    Chen, Y. Q.
    McCauley, M.
    Gamble, T.
    Hosseinipour, M. C.
    Kumarasamy, N.
    Hakim, J. G.
    Kumwenda, J.
    Grinsztejn, B.
    Pilotto, J. H. S.
    Godbole, S. V.
    Chariyalertsak, S.
    Santos, B. R.
    Mayer, K. H.
    Hoffman, I. F.
    Eshleman, S. H.
    Piwowar-Manning, E.
    Cottle, L.
    Zhang, X. C.
    Makhema, J.
    Mills, L. A.
    Panchia, R.
    Faesen, S.
    Eron, J.
    Gallant, J.
    Havlir, D.
    Swindells, S.
    Elharrar, V.
    Burns, D.
    Taha, T. E.
    Nielsen-Saines, K.
    Celentano, D. D.
    Essex, M.
    Hudelson, S. E.
    Redd, A. D.
    Fleming, T. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (09): : 830 - 839
  • [34] HIV-1 neuroimmunity in the era of antiretroviral therapy
    Kraft-Terry, Stephanie D.
    Stothert, Andrew R.
    Buch, Shilpa
    Gendelman, Howard E.
    NEUROBIOLOGY OF DISEASE, 2010, 37 (03) : 542 - 548
  • [36] Oxidative Imbalance in HIV-1 Infected Patients Treated with Antiretroviral Therapy
    Mandas, Antonella
    Iorio, Eugenio Luigi
    Congiu, Maria Gabriella
    Balestrieri, Cinzia
    Mereu, Antonello
    Cau, Daniela
    Dessi, Sandra
    Curreli, Nicoletta
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2009,
  • [37] Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy
    Quiros-Roldan, E
    Signorini, S
    Castelli, F
    Torti, C
    Patroni, A
    Airoldi, M
    Carosi, G
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2001, 15 (01) : 43 - 46
  • [38] Coccidioidomycosis in Patients with HIV-1 Infection in the Era of Potent Antiretroviral Therapy
    Masannat, Fares Y.
    Ampel, Neil M.
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (01) : 1 - 7
  • [39] Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
    Archin, N. M.
    Liberty, A. L.
    Kashuba, A. D.
    Choudhary, S. K.
    Kuruc, J. D.
    Crooks, A. M.
    Parker, D. C.
    Anderson, E. M.
    Kearney, M. F.
    Strain, M. C.
    Richman, D. D.
    Hudgens, M. G.
    Bosch, R. J.
    Coffin, J. M.
    Eron, J. J.
    Hazuda, D. J.
    Margolis, D. M.
    NATURE, 2012, 487 (7408) : 482 - U1650
  • [40] Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
    N. M. Archin
    A. L. Liberty
    A. D. Kashuba
    S. K. Choudhary
    J. D. Kuruc
    A. M. Crooks
    D. C. Parker
    E. M. Anderson
    M. F. Kearney
    M. C. Strain
    D. D. Richman
    M. G. Hudgens
    R. J. Bosch
    J. M. Coffin
    J. J. Eron
    D. J. Hazuda
    D. M. Margolis
    Nature, 2012, 487 : 482 - 485